CRVS vs. CTXR, PMVP, RLMD, ACET, CLRB, RZLT, CNTB, ABEO, IMUX, and ALLK
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Citius Pharmaceuticals (CTXR), PMV Pharmaceuticals (PMVP), Relmada Therapeutics (RLMD), Adicet Bio (ACET), Cellectar Biosciences (CLRB), Rezolute (RZLT), Connect Biopharma (CNTB), Abeona Therapeutics (ABEO), Immunic (IMUX), and Allakos (ALLK). These companies are all part of the "pharmaceutical preparations" industry.
Citius Pharmaceuticals (NASDAQ:CTXR) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 15.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Citius Pharmaceuticals had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 0.68 beat Citius Pharmaceuticals' score of 0.53 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.
Corvus Pharmaceuticals received 80 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 62.31% of users gave Corvus Pharmaceuticals an outperform vote while only 62.05% of users gave Citius Pharmaceuticals an outperform vote.
Citius Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Citius Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 515.38%. Corvus Pharmaceuticals has a consensus price target of $6.88, suggesting a potential upside of 204.20%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Corvus Pharmaceuticals.
Corvus Pharmaceuticals' return on equity of -40.78% beat Citius Pharmaceuticals' return on equity.
Summary
Citius Pharmaceuticals beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Corvus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
Related Companies and Tools
